Reported sales decreased by 14.6%, and excluding the impact of foreign currency, sales decreased 11.5% compared to third quarter 2009.

Adjusted EBITDA was $8.5 million in the third quarter 2010 compared to $11.0 million in the same quarter last year.

Debt, net of cash was $71.4 million at the end of third quarter 2010, a decrease of $5.5 million during the quarter including a positive $2.5 million impact of currency on foreign cash balances.

Acquired a 51% stake in Zenara Pharma, a Hyderabad, India based pharmaceutical company focused on the formulation of final dosage form products, for $20 million on November 2, 2010.

Narrowed the range of 2010 full year guidance for sales, excluding the impact of foreign currency, to a decline of between 3% and 5%, and Adjusted EBITDA to $41 to $44 million.

Basis of ReportingThe Company has provided a reconciliation from adjusted amounts to GAAP amounts at the end of this press release. Management believes that the adjusted amounts provide a more meaningful representation of the Company's operating results for the periods presented due to the magnitude and nature of certain expenses recorded.

Third Quarter 2010 Operating Results – Continuing OperationsThird quarter 2010 sales of $49.4 million were 14.6% lower than the third quarter 2009. Excluding a 3.1% unfavorable impact of foreign exchange, reflecting a stronger U.S. dollar, sales decreased 11.5%. The decrease is primarily due to the timing of orders for certain products, the effects of a supply chain disruption at a customer's facility, a negotiated contract extension for certain drug delivery products resulting in lower volumes and pricing, and lower custom development and controlled substances shipments. These decreases were partially offset by higher sales volume of generic active pharmaceutical ingredients ("APIs").

Third quarter 2010 Gross Margin decreased to 28.6%, but was flat compared to 29.3% in the third quarter 2009 after excluding the impact of foreign currency. Gross margins were positively impacted by lower production costs, offset by lower pricing.

Selling, General and Administrative Expenses in the third quarter 2010 were $7.9 million compared to $9.3 million in the same period last year. The decrease is a result of lower legal fees and insurance premiums.

Research and Development ("R&D") Expenses increased to $3.1 million in the third quarter 2010 from $2.0 million in the third quarter 2009 primarily due to the March 2010 acquisition of IEP, reduced utilization of certain R&D personnel on revenue-generating custom development projects resulting in these costs being expensed rather than absorbed into cost of sales or inventory and the development of new products and technology platforms.

Merger and Acquisition Expenses totaling $0.7 million in the third quarter 2010 include costs related to the acquisition of a 51% equity stake in Zenara Pharma.

As a result of the above items, Operating Profit decreased to $1.3 million in the third quarter 2010 from $5.6 million in the third quarter 2009. Adjusted Operating Profit was $3.2 million compared to $5.6 million for the third quarter last year. The decrease in Adjusted Operating Profit was driven primarily by lower gross profits described above.

The Provision for Income Taxes totaled $1.3 million in the third quarter 2010. The Company's effective tax rate has been and is expected to remain highly sensitive to the geographic mix of income due to the Company's inability to recognize tax benefits where there has been a recent history of losses, primarily in the U.S.

Net Loss for the third quarter 2010 was $1.5 million or $0.05 per share compared to Net Income of $3.0 million or $0.10 per share in the third quarter 2009.

Capital expenditures and depreciation for the third quarter 2010 were $3.5 million and $5.3 million compared to $3.3 million and $5.4 million in the third quarter 2009, respectively.

Steven M. Klosk, President and Chief Executive Officer, said, "Third quarter results primarily reflect the impact of the timing of shipments on our business. We currently expect much stronger fourth quarter volumes for our larger APIs, but lower revenue expectations for our custom development business, where we provide products and services for clinical phase projects, led us to lower the high end of our sales and profit guidance accordingly. We continue to be encouraged by the increasing number of requests for proposals for clinical development projects, and the higher percentage of later stage projects on which we are bidding. Generic order levels continue to be much stronger than prior year and we expect our controlled substances business to show solid growth for the full year. As part of our ongoing efforts to reduce costs within our business, we restructured one of our manufacturing sites during the third quarter, resulting in a charge for the associated reduction in workforce.

"As we announced Tuesday, we acquired a 51% stake in Zenara Pharma, a Hyderabad, India based pharmaceutical company focused on the formulation of final dosage form products. We are very excited about the growth opportunities that this investment will bring to Cambrex. The integration of Cambrex's API and drug delivery business with Zenara's formulation and finished dosage capabilities will enable us to provide greater value to our pharmaceutical customers. The combination of our two businesses gives Cambrex a leading position within the nicotine replacement therapy market, supplying both APIs and finished dosage form products. The Cambrex Zenara technology and cost position will enable us to effectively provide smoking cessation products to our customers for new, potentially large emerging markets. This investment also gives us a foothold in the growing Indian pharmaceutical market and will allow us to expand our access to new product categories, geographies and customers."

Guidance – Continuing OperationsThe Company currently expects that sales for 2010, excluding the impact of foreign currency, will be between a decline of 3% and 5% versus 2009, and that full year 2010 Adjusted EBITDA will be between $41 and $44 million.

For 2010, capital expenditures are expected to be approximately $12 to $14 million and depreciation is expected to be $21 to $22 million.

The financial information contained in this press release is unaudited, subject to revision and should not be considered final until the third quarter 2010 Form 10-Q is filed with the SEC.

Conference Call and WebcastThe Conference Call to discuss third quarter 2010 results will begin at 8:30 a.m. Eastern Time on Thursday, November 4, 2010 and last approximately 45 minutes. Those wishing to participate should call 1-800-768-6569 for domestic and +1-785-830-7992 for international. Please use the pass code 2045587 and call approximately 10 minutes prior to start time. A webcast is available from the Investors section on the Cambrex website located at www.cambrex.com and can be accessed for 30 days following the conference call. A telephone replay of the conference call will be available through Thursday, November 11, 2010 by calling 1-888-203-1112 for domestic and +1-719-457-0820 for international. Please use the pass code 2045587 to access the replay.

Forward Looking StatementsThis document may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under The Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding expected performance, especially expectations with respect to sales, research and development expenditures, earnings per share, capital expenditures, acquisitions, divestitures, collaborations, or other expansion opportunities. These statements may be identified by the fact that they use words such as "expects," "anticipates," "intends," "estimates," "believes" or similar expressions in connection with any discussion of future financial and operating performance. Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout the Company's public filings. Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations including, but not limited to, global economic trends, pharmaceutical outsourcing trends, competitive pricing or product developments, government legislation and regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation disclosed in the Company's public filings, the Company's ability to satisfy the continued listing standards of the New York Stock Exchange, changes in foreign exchange rates, uncollectible receivables, loss on disposition of assets, cancellation or delays in renewal of contracts, lack of suitable raw materials or packaging materials, the Company's ability to receive regulatory approvals for its facilities or products and other factors described under the caption "Risk Factors That May Affect Future Results" in the Company's Annual Report on Form 10-K for the year ended December 31, 2009. Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time and it is not possible for the Company to predict which will arise. In addition, the Company cannot assess the impact of each factor on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

For further details and a discussion of these and other risks and uncertainties, investors are cautioned to review the Cambrex 2009 Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other filings with the U.S. Securities and Exchange Commission.

About CambrexCambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. We offer Active Pharmaceutical Ingredients ("APIs"), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit www.cambrex.com. CAMBREX CORPORATIONStatements of Profit and LossFor the Quarters Ended September 30, 2010 and 2009(in thousands)20102009% of% ofAmountSalesAmountSalesGross Sales

$

49,356100.0%$

57,802100.0%Allowances and Rebates4921.0%2850.5%Net Sales48,86499.0%57,51799.5%Other Revenues(1,090)-2.2%(1,147)-2.0%Net Revenues47,77496.8%56,37097.5%Cost of Goods Sold33,66468.2%39,42268.2%Gross Profit14,11028.6%16,94829.3%Operating ExpensesSelling, General and Administrative Expenses7,87916.0%9,29516.1%Research and Development Expenses3,0806.2%2,0263.5%Restructuring Expenses1,1872.5%-0.0%Merger and Acquisition Expenses7111.4%-0.0%Total Operating Expenses12,85726.1%11,32119.6%Operating Profit1,2532.5%5,6279.7%Other Expenses/(Income):Interest Expense, net1,2332.5%1,1111.9%Other Expense/(Income), net520.1%(31)-0.1%(Loss)/Income Before Income Taxes(32)-0.1%4,5477.9%Provision for Income Taxes1,2522.5%1,5842.8%(Loss)/Income from Continuing Operations

37,725* During the third quarter 2010, the Company incurred expenses related to certain one-time employee benefits relating to a plan to restructure its operations at a manufacturing site. These costs are identified within the 2010 income statement and have been excluded from the calculation of certain profit measurements, including Adjusted EBITDA for 2010. ** During 2010, the Company incurred Merger and Acquisition Expenses pursuant to the acquisition of a 51% equity stake in Zenara Pharma. These costs are identified within the 2010 income statement and have been excluded from the calculation of certain profit measurements, including Adjusted EBITDA for 2010. CAMBREX CORPORATIONConsolidated Balance SheetsAs of September 30, 2010 and December 31, 2009(in thousands)September 30,December 31,Assets20102009Cash and Cash Equivalents

$

42,996$

52,365Trade Receivables, net30,98932,025Inventories, net66,28858,369Prepaid Expenses and Other Current Assets8,4976,654 Total Current Assets148,770149,413Property, Plant and Equipment, net153,614161,149Goodwill and Intangibles, net43,19936,360Other Non-Current Assets4,0954,593 Total Assets

$

349,678$

351,515Liabilities and Stockholders' EquityAccounts Payable

$

18,123$

17,038Accrued Expenses and Other Current Liabilities36,91038,013 Total Current Liabilities55,03355,051Long-term Debt114,400120,800Deferred Income Taxes18,38817,305Accrued Pension and Postretirement Benefits41,50640,963Other Non-Current Liabilities13,10214,126 Total Liabilities

(Date:12/8/2016)... 8, 2016 Biotheranostics today announced that new ... the Breast Cancer Index (BCI) in identifying which ... most at-risk for disease recurrence and might benefit ... three studies advancing the understanding of the value ... biology and inform decisions related to patient treatment. ...

(Date:12/8/2016)... ... December 08, 2016 , ... ... World Technology Awards. uBiome is one of just six company finalists in the ... In addition to uBiome, companies nominated as finalists in this year’s awards include ...